Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 7/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086225 | 0.91 | F2 (0.44) | F2USP30LARS1F10PLG | |
| Trifluoroacetic Acid SCHEMBL3097684 | 0.84 | F2 (0.46) | F2LARS1PLG | |
| Trifluoroacetic Acid SCHEMBL15000275 | 0.84 | ITGB3 (0.44) | F2SLC6A2SLC6A4LARS1CTSD | |
| Trifluoroacetic Acid SCHEMBL14999886 | 0.84 | ITGB3 (0.47) | F2SLC6A2SLC6A4LARS1SLC6A3 | |
| SCHEMBL3096957 | 0.83 | PTPN2 (0.47) | F2 | |
| SCHEMBL14999923 | 0.82 | MAPT (0.46) | F2LARS1 | |
| SCHEMBL14999932 | 0.81 | LARS1 (0.47) | F2LARS1 | |
| SCHEMBL3090331 | 0.81 | LARS1 (0.47) | F2LARS1 | |
| SCHEMBL3090750 | 0.81 | LARS1 (0.45) | F2LARS1 | |
| SCHEMBL3102970 | 0.81 | MMP9 (0.46) | F2LARS1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | F2 4128/4885SLC6A2 652/4885SLC6A4 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.